Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial with its Novel Ghrelin Agonist, TZP-101, for Post-Operative Ileus

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESS WIRE)--Tranzyme Pharma, a leading biopharmaceutical company developing small molecule drugs for the treatment of gastrointestinal and metabolic diseases, today announced the initiation of a Phase IIb clinical trial of its investigational drug, TZP-101, for the management of post-operative ileus (POI). TZP-101 is a potent ghrelin agonist that Tranzyme is developing as a first-in-class prokinetic agent for the treatment of POI and severe gastroparesis.